Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis

New England Journal of Medicine

Volumn 365, Issue 12, 2011, Pages 1079-1087

  Richeldi, Luca ^a   Costabel, Ulrich ^b   Selman, Moises ^c   Kim, Dong Soon ^d   Hansell, David M ^e,f   Nicholson, Andrew G ^e,f   Brown, Kevin K ^h   Flaherty, Kevin R ⁱ   Noble, Paul W ^j   Raghu, Ganesh ^k   Brun, Michèle ^l   Gupta, Abhya ^m   Juhel, Nolwenn ^l   Klüglich, Matthias ^m   Du Bois, Roland M ^g  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^b UNIVERSITY OF DUISBURG ESSEN   (Germany)

^c INSTITUTO NACIONAL DE ENFERMEDADES RESPIRATORIAS   (Mexico)

^d University of Ulsan   (South Korea)

^e ROYAL BROMPTON HOSPITAL   (United Kingdom)

^f NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^g IMPERIAL COLLEGE LONDON   (United Kingdom)

^h DEPARTMENT OF MEDICINE   (United States)

ⁱ UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^j DUKE UNIVERSITY MEDICAL CENTER   (United States)

^k UNIVERSITY OF WASHINGTON   (United States)

^l BOEHRINGER INGELHEIM   (France)

^m NONE

more..

Author keywords

[No Author keywords available]

Indexed keywords

INTEDANIB; PLACEBO;

ABDOMINAL PAIN; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BRONCHITIS; CONTROLLED STUDY; COUGHING; DIARRHEA; DISEASE EXACERBATION; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; GASTROINTESTINAL SYMPTOM; HEART DISEASE; HUMAN; INFECTION; INFESTATION; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM DISEASE; NAUSEA; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY TRACT DISEASE; SCORING SYSTEM; SIDE EFFECT; THORAX DISEASE; TOTAL LUNG CAPACITY; VOMITING;

EID: 80053091084     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1103690     Document Type: Article

References (22)

1. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001;134:136-51. (Pubitemid 32096342)
2. De Vries J, Kessels BL, Drent M. Quality of life of idiopathic pulmonary fibrosis patients. Eur Respir J 2001;17:954-61. (Pubitemid 32600345)
3. Ley B, Collard HR, King TE Jr. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;183:431-40.
4. Collard HR, Moore BB, Flaherty KR, et al. Acute exacerbations of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2007;176:636-43. (Pubitemid 47503070)
5. Hilberg F, Roth GJ, Krssak M, et al. BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy. Cancer Res 2008;68:4774-82.
6. Coward WR, Saini G, Jenkins G. The pathogenesis of idiopathic pulmonary fibrosis. Ther Adv Respir Dis 2010;4:367-88.
7. Allen JT, Spiteri MA. Growth factors in idiopathic pulmonary fibrosis: relative roles. Respir Res 2002;3:13.
8. Grimminger F, Schermuly RT, Ghofrani HA. Targeting non-malignant disorders with tyrosine kinase inhibitors. Nat Rev Drug Discov 2010;9:956-70.
9. Chaudhary NI, Roth GJ, Hilberg F, et al. Inhibition of PDGF, VEGF and FGF signalling attenuates fibrosis. Eur Respir J 2007;29:976-85. (Pubitemid 46711904)
10. Abdollahi A, Li M, Ping G, et al. Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med 2005;201:925-35. (Pubitemid 40524462)
11. Yu C, Wang F, Jin C, et al. Role of fibroblast growth factor type 1 and 2 in carbon tetrachloride-induced hepatic injury and fibrogenesis. Am J Pathol 2003; 163:1653-62. (Pubitemid 37175112)
12. Hamada N, Kuwano K, Yamada M, et al. Anti-vascular endothelial growth factor gene therapy attenuates lung injury and fibrosis in mice. J Immunol 2005;175: 1224-31. (Pubitemid 41095011)
13. American Thoracic Society, European Respiratory Society. Idiopathic pulmonary fibrosis: diagnosis and treatment: international consensus statement. Am J Respir Crit Care Med 2000;161:646-64.
14. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005;26:319-38. (Pubitemid 41079078)
15. Du Bois RM, Weycker D, Albera C, et al. Six-minute-walk test in idiopathic pulmonary fibrosis: test validation and minimal clinically important difference. Am J Respir Crit Care Med 2011;183:1231-7.
16. Jones PW, Quirk FH, Baveystock CM. The St. George's Respiratory Questionnaire. Respir Med 1991;85:Suppl B:25-31.
17. Jones PW. St. George's Respiratory Questionnaire: MCID. COPD 2005;2:75-9.
18. Swigris JJ, Brown KK, Behr J, et al. The SF-36 and SGRQ: validity and first look at minimum important differences in IPF. Respir Med 2010;104:296-304.
19. Hyzy R, Huang S, Myers J, Flaherty K, Martinez F. Acute exacerbation of idiopathic pulmonary fibrosis. Chest 2007;132:1652-8. (Pubitemid 350156025)
20. Martinez FJ, Safrin S, Weycker D, et al. The clinical course of patients with idiopathic pulmonary fibrosis. Ann Intern Med 2005;142:963-7.
21. Swigris JJ, Gould MK, Wilson SR. Health-related quality of life among patients with idiopathic pulmonary fibrosis. Chest 2005;127:284-94. (Pubitemid 41724589)
22. Wells AU, Behr J, Silver R. Outcome measures in the lung. Rheumatology (Oxford) 2008;47:Suppl 5:v48-v50.